“The Company anticipates that this acquisition will help enable efficiencies and scale-up of operations. The Company believes that integration of the companies can result in:
A fully integrated platform combining the technologies, expertise and intellectual property of NWBio, Advent and Flaskworks; Streamlining and efficiencies in supply chain management and facilities management; Closing of operations at the GMP facility in London and reallocation of resources to the Sawston, UK facility and to capacity development in the US; Facilitating scale-up of manufacturing capacity; Streamlining and efficiencies in interactions with clinical sites and distribution of DCVax products.” — NWBIO